People · Operator
Named in public records as an officer, director or promoter · active 2010–2020 · Biotechnology, Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Liquidia Technologies Inc | — | Biotechnology | Series B | $86.7M | $890.0M | 2011 |
| Edison Pharmaceuticals Inc | — | Biotechnology | Series C | $80.2M | $2.0B | 2011 |
| InCarda Therapeutics, Inc. | — | Pharmaceuticals | Series B | $66.3M | $856.6M | 2017 |
| Amylyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $65.1M | $1.0B | 2017 |
| Tallac Therapeutics, Inc. | — | Pharma | Series C | $61.6M | $2.2B | 2020 |
| Bioscale Inc | — | Biotechnology | Series B | $44.7M | $747.7M | 2010 |
| Meissa Vaccines Inc | — | Biotechnology | Series A | $15.2M | $503.1M | 2019 |
| Adjuvance Technologies Inc. | — | Biotechnology | Series A | $13.4M | $385.3M | 2019 |
| Torpedo Diagnostics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2017 |
Isaac Cheng at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac Cheng on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Somu Subramaniam | 1 | 17 |
| Stephen Bloch | 1 | 15 |
| Corey Goodman | 1 | 13 |
| Ed Mathers | 1 | 11 |
| Peter B. Finn | 1 | 11 |
| William F. Doyle | 1 | 8 |
| Joshua Cohen | 1 | 8 |
| Michael Carusi | 1 | 7 |
| Alan Colowick | 1 | 7 |
| Stephanie O'Brien | 1 | 7 |
| Andrew ElBardissi | 1 | 7 |
| Seth Rudnick | 1 | 5 |
| Paul Billings | 1 | 5 |
| Joseph DeSimone | 1 | 5 |
| Peter Finn | 1 | 5 |
| Edward Crawley | 1 | 4 |
| Grace Colon | 1 | 4 |
| Ralph Snyderman | 1 | 4 |
| Jeffrey Gardner | 1 | 4 |
| William Doyle | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.